Karyopharm Therapeutics Inc.
KPTI
$7.46
$1.1518.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -256.57% | 37.20% | 26.43% | 7.05% | 172.91% |
| Total Depreciation and Amortization | -14.29% | -8.24% | 5.19% | 3.75% | 9.64% |
| Total Amortization of Deferred Charges | 94.70% | 1,137.02% | 986.18% | 1,074.15% | 631.41% |
| Total Other Non-Cash Items | 110.51% | -510.15% | -265.25% | -108.45% | -1,177.25% |
| Change in Net Operating Assets | 206.08% | 85.77% | -49.95% | 1,808.74% | -685.90% |
| Cash from Operations | 51.43% | 10.84% | -38.88% | 34.12% | -49.81% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.33% | -30.93% | -45.07% | 197.25% | 142.14% |
| Cash from Investing | -64.33% | -30.32% | -44.88% | 197.25% | 142.14% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -53.89% | -- | 157.58% | -- | -10.23% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.13% | -- | 157.58% | -- | 4,663.49% |
| Foreign Exchange rate Adjustments | 172.73% | 131.25% | -122.47% | 169.23% | 57.69% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.09% | -8.67% | -220.23% | 67.95% | 1,554.22% |